Biotechnology: In Vitro & In Vivo Diagnostic Substances Stocks
17 biotechnology: in vitro & in vivo diagnostic substances stocks ranked by market capitalization. Updated October 11, 2026.
MetaCap tracks 17 US-listed companies in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry, part of the broader Health Care sector, worth a combined $62.55B. The largest biotechnology: in vitro & in vivo diagnostic substances stocks are IDEXX Laboratories (IDXX, $40.8B), Lantheus (LNTH, $6.5B) and Oruka Therapeutics (ORKA, $5.4B). The biggest company alone accounts for about 65% of the industry's total market value, and the median member is worth $474.6M. On the latest trading day, 15 of 17 biotechnology: in vitro & in vivo diagnostic substances stocks shown were higher, with an average move of +2.52%; Trinity Biotech (TRIB) led with a 13.49% gain.
Summary generated from market data by MetaCap's automated system. Methodology
Largest biotechnology: in vitro & in vivo diagnostic substances stocks by market cap
| # | Symbol | Company | Price | % Change | Volume | Market Cap |
|---|---|---|---|---|---|---|
| 1 | IDXX | IDEXX Laboratories Inc. | 518.00 | +0.95% | 466.78K | $40.81B |
| 2 | LNTH | Lantheus Holdings Inc. | 100.15 | +0.03% | 955.50K | $6.54B |
| 3 | ORKA | Oruka Therapeutics Inc. | 82.11 | +6.25% | 1.21M | $5.44B |
| 4 | NEOG | Neogen Corporation | 11.85 | +1.20% | 3.65M | $2.59B |
| 5 | CLDX | Celldex Therapeutics Inc. | 29.89 | +2.01% | 992.78K | $2.35B |
| 6 | NTLA | Intellia Therapeutics Inc. | 13.07 | +3.73% | 8.15M | $1.83B |
| 7 | QDEL | QuidelOrtho Corporation | 13.42 | +8.14% | 3.58M | $920.28M |
| 8 | ACHV | Achieve Life Sciences Inc. | 7.41 | +3.06% | 987.30K | $763.99M |
| 9 | TKNO | Alpha Teknova Inc. | 8.84 | +4.74% | 195.40K | $474.60M |
| 10 | MYGN | Myriad Genetics Inc. | 4.31 | +2.62% | 1.37M | $412.25M |
| 11 | NNNN | Anbio Biotechnology Class A | 4.66 | +0.87% | 69.81K | $204.53M |
| 12 | IMDX | Insight Molecular Diagnostics Inc. | 3.37 | +2.74% | 156.36K | $110.28M |
| 13 | ICCC | ImmuCell Corporation | 9.80 | +0.51% | 1.86K | $89.01M |
| 14 | BMRA | Biomerica Inc. | 1.84 | -1.86% | 10.30K | $8.44M |
| 15 | TRIB | Trinity Biotech plc ADR | 6.86 | +13.49% | 33.93K | $5.57M |
| 16 | CDIO | Cardio Diagnostics Holdings Inc. | 1.87 | +0.36% | 15.99K | $5.53M |
| 17 | VRAX | Virax Biolabs Group Limited | 1.87 | -6.03% | 88.54K | $2.52M |
Frequently asked questions
- How many biotechnology: in vitro & in vivo diagnostic substances stocks are there?
- MetaCap tracks 17 US-listed stocks in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry, with a combined market value of about $62.55B.
- What is the largest biotechnology: in vitro & in vivo diagnostic substances company?
- IDEXX Laboratories (IDXX) is the largest biotechnology: in vitro & in vivo diagnostic substances stock by market capitalization, at about $40.81B.
- What sector is the biotechnology: in vitro & in vivo diagnostic substances industry in?
- The Biotechnology: In Vitro & In Vivo Diagnostic Substances industry belongs to the Health Care sector. Sectors are broad groupings of related industries; industries group companies with very similar products or business models.
- How are biotechnology: in vitro & in vivo diagnostic substances stocks doing today?
- As of October 11, 2026, the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry is up 1.62% on a market-cap-weighted basis.
Explore more
Prices as of Oct 11, 5:00 PM EDT. Market data is delayed at least 15 minutes and provided for informational purposes only. Not investment advice. Full disclaimer